IDH2 and glioblastoma: Interestingly, however, there are clear studies that provide a different therapy recommendation for patients with AA with and without IDH mutation [8], but not for the recommendation to treat patients with AA IDH-wt (and MGMT promoter methylation) identically to GBM patients.